New drug combo targets leukemia that Won't quit
NCT ID NCT05024552
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 28 times
Summary
This early-stage study tests a combination of two drugs, Vyxeos and Gilteritinib, for adults with a specific genetic form of acute myeloid leukemia (FLT3-mutated) that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well it controls the disease. Participants receive the drugs in phases, and some may continue on daily Gilteritinib to keep the leukemia in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.